Repurposed Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Repurposed Therapeutics, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MOSIQUEL and DEFENDER PHARMACEUTICALS. The owner is based in Tampa, FL.
324 S. Hyde Park Ave, Suite 350
Tampa, FL 33606
Showing of trademarks Trademarks
Trademark Classifications
Repurposed Therapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Repurposed Therapeutics, Inc. have?
Repurposed Therapeutics, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 abandoned, 1 cancelled.
What trademark classes does Repurposed Therapeutics, Inc. file in?
Repurposed Therapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Repurposed Therapeutics, Inc.'s most well-known trademarks?
Repurposed Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as MOSIQUEL and DEFENDER PHARMACEUTICALS. These are among 2 currently registered trademarks in the portfolio.
What is Repurposed Therapeutics, Inc.'s trademark registration success rate?
Repurposed Therapeutics, Inc. has a 22% trademark registration rate, with 2 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.